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The interactions between CD80 and CD86 on antigen-presenting cells and CD28 on T cells serve as an
important costimulatory signal in the activation of T cells. Although the simplistic two-signal hypothesis has
been challenged in recent years by the identification of different costimulators, this classical pathway has been
shown to significantly impact antiviral humoral and cellular immune responses. How the CD80/CD86-CD28
pathway affects the control of chronic or latent infections has been less well characterized. In this study, we
investigated its role in antiviral immune responses against murine gammaherpesvirus 68 (MHV-68) and
immune surveillance using CD80/CD86/ mice. In the absence of CD80/CD86, primary antiviral CD8 T-cell
responses and the induction of neutralizing antibodies were severely impaired. During long-term immune
surveillance, the virus-specific CD8 T cells were impaired in IFN- production and secondary expansion and
exhibited an altered phenotype. Surprisingly, a low level of viral reactivation in the lung was observed, and this
effect was independent of CD28 and CTLA-4. Thus, CD80 and CD86, signaling through CD28 and possibly
another unidentified receptor, are required for optimal immune surveillance and antiviral immune responses
to murine gammaherpesvirus.
Costimulation through the CD80/CD86-CD28 pathway is
a key event in the induction of both humoral and cellular
immune responses. CD80 and CD86 are upregulated on
mature antigen-presenting cells (APCs) and bind to CD28
on the T cell, transducing a crucial second signal for T-cell
activation along with the T-cell receptor (7). CD28 signal-
ing, thought to be mediated through the phosphatidylinosi-
tol 3-kinase–protein kinase B (Akt) pathway and growth
factor-receptor-bound protein 2 (Grb2), results in increased
interleukin-2 (IL-2) production, upregulation of CD25 (the
IL-2 receptor  chain), entry of the T cell into the cell cycle,
and enhanced T-cell survival through the upregulation of
the antiapoptotic molecule Bcl-XL (1, 49). Engagement of
CD28 mediates recruitment of lipid rafts to the immunolog-
ical synapse, which lowers the activation threshold of the T
cell and amplifies the magnitude of the overall T-cell re-
sponse (1). Once T cells are activated, they upregulate ex-
pression of cytotoxic T-lymphocyte antigen 4 (CTLA-4),
another receptor for CD80/CD86. CTLA-4 negatively reg-
ulates T-cell responses by the following mechanisms: se-
questering CD80 and CD86 away from CD28 by its high
affinity to these molecules; recruiting phosphatases such as
Src homology region 2 domain-containing phosphatase 1
(SHP-1) and -2, thereby, dephosphorylating downstream
signals of the TCR; and transducing a signal into the APCs,
resulting in the induction of indoleamine 2,3-dioxygenase
and the catabolism of tryptophan, creating an inhibitory
environment for the T cell (13, 18, 19). In addition to these
well-characterized signals mediated by CD80/CD86, several
studies have indicated that CD80/CD86 may transduce sig-
nals independent of CD28 and CTLA-4 (28, 57).
The role of CD80/CD86-CD28 costimulation in the initia-
tion of antiviral T-cell responses has been studied in several
infection models. Dependency on this costimulatory signal var-
ies according to the identity of the virus. Primary CD8 T-cell
responses in CD28/, CD80/CD86/, or CTLA-4-immuno-
globulin (Ig)-treated mice are greatly attenuated after infec-
tion with influenza virus, herpes simplex virus type 1, or vesic-
ular stomatitis virus (VSV) (4, 12, 29, 44), and responses to
lymphocytic choriomeningitis virus (LCMV) are slightly re-
duced in CD28/ or CTLA-4 transgenic mice (2, 8, 42, 59). A
decrease in the frequency of virus-specific memory CD8 T
cells was also observed in the LCMV and influenza virus mod-
els. Furthermore, the signal is critical for the production of
neutralizing antibodies (Abs), mainly due to its requirement
for the generation of germinal centers and thus class switch
recombination (5, 29, 44, 59).
Despite the well-characterized role of the CD80/CD86-
CD28 axis in acute infections, its role in chronic viral infections
is poorly studied. This question is particularly interesting be-
cause in human Epstein-Barr virus and cytomegalovirus infec-
tions, virus-specific CD8 T cells show dynamic regulation of
CD28 expression during differentiation (25), indirectly suggest-
ing the role of this interaction in shaping the T-cell response
against these viruses. In support of the idea that signaling
through CD28 is important in chronic infections, infection of
CD28/ mice with high-titer chronic LCMV (clone 13) re-
sulted in an impaired memory CD8 T-cell frequency and
increased viral titer (8). Furthermore, Kemball et al. recently
reported that CD80/CD86 blockade along with blocking
CD40L-CD40 interactions during priming lead to a signifi-
* Corresponding author. Mailing address: Department of Microbi-
ology and Immunology, 1 Medical Center Dr., Lebanon, NH 03756.
Phone: (603) 650-7730. Fax: (603) 650-6223. E-mail: edward.j.usherwood
@dartmouth.edu.
9159
cantly reduced antiviral CD8 T-cell response and increased
viral burden in a murine polyomavirus model (23).
Murine gammaherpesvirus 68 (MHV-68) initially replicates
in the lung after intranasal infection and then establishes a
latent infection. The latent infection is primarily in B lympho-
cytes (41) but also occurs in macrophages (53), dendritic cells
(15), and lung epithelial cells (39). During the persistent phase
of infection, there is believed to be only very-low-level expres-
sion of viral antigens, unlike other commonly studied chronic
virus infection models such as persistent strains of LCMV (54).
Therefore, this model is very relevant for understanding im-
mune responses in human gammaherpesvirus infections such
as EBV and human herpesvirus 8. In addition, data obtained
with this model may be relevant for other human and animal
persistent infections where the virus is present at only very low
levels.
Here we report that CD80 and CD86 control antiviral im-
mune responses and immune surveillance of MHV-68 through
CD28-dependent and -independent signals. We show that in
the absence of either CD80/CD86 or CD28, the primary virus-
specific CD8 T-cell response and Ab response were signifi-
cantly impaired. Furthermore the antiviral memory CD8 T
cells were impaired in their ability to produce gamma inter-
feron (IFN-) and proliferate upon secondary antigenic chal-
lenge and were altered in phenotype, suggesting impaired
differentiation. In addition, our data point to a CD28-indepen-
dent CD80/CD86 signal that is required for effective immune
surveillance against MHV-68 reactivation. These results de-
scribe a previously undefined role of CD80/CD86 in control-
ling antigammaherpesvirus CD8 T-cell responses and in im-
mune surveillance to the virus.
MATERIALS AND METHODS
Mice, virus, and reagents. MHV-68 virus (clone G2.4) was originally obtained
from A. A. Nash (University of Edinburgh, Edinburgh, United Kingdom). Virus
was propagated and the titer was determined as previously described (40). A
recombinant vaccinia virus expressing the open reading frame 61524–531
(ORF61524–531)/Kb epitope (rVV-ORF61) of MHV-68 was obtained from Peter
Doherty (St. Jude Children’s Research Hospital, Memphis, TN) (36). A recom-
binant gammaherpesvirus 68 strain containing a frameshift mutation in ORF73
(FS73) and the revertant virus (FS73R) were provided by Stacey Efstathiou
(University of Cambridge, Cambridge, United Kingdom) (17). For MHV-68
infections, mice were infected intranasally with 400 PFU under anesthesia with
2,2,2-tribromoethanol. For vaccinia virus challenge, mice were given 106 PFU of
rVV-ORF61 intraperitionally.
C57BL/6 mice were purchased from The National Cancer Institute (Bethesda,
MD). CD80/CD86/ mice on the C57BL/6 background were obtained from
Lloyd Kasper (Dartmouth Medical School, Hanover, NH), and CD28/,
CD80/, and CD86/ mice were obtained from The Jackson Laboratory (Bar
Harbor, ME) and bred in the Dartmouth-Hitchcock Medical Center mouse
facility. The Animal Care and Use Program of Dartmouth College approved all
animal experiments.
Anti-CTLA-4 monoclonal antibody (MAb), clone UC10-4F10-11, was purified
from culture supernatants of hybridoma obtained from the American Type
Culture Collection (ATCC no. HB304). The T-Gel purification kit (Pierce Bio-
technology, Rockford, IL) was used for MAb purification. Two hundred micro-
grams of the MAb was injected intraperitoneally every 2 to 3 days.
Tissue preparation. Single-cell suspensions of spleens and mediastinal lymph
nodes (MLNs) were prepared by passing through cell strainers. Lungs were
injected with 2 ml of minimal essential medium containing 417.5 g/ml Liberase
CI and 200 g/ml DNase I (both obtained from Roche, Indianapolis, IN),
minced with scissors, and then incubated for 30 min at 37°C and passed through
cell strainers. Suspensions were resuspended in 80% isotonic Percoll and subse-
quently overlaid with 40% isotonic Percoll. Samples were then centrifuged at
400  g for 25 min at 4°C, and the cells at the 80%/40% interface were collected,
washed, and counted.
MHC/peptide tetramer, antibody staining, and flow cytometric analysis. Ma-
jor histocompatibility complex (MHC)/peptide tetramers for the ORF61524–531/Kb
(TSINFVKI) and ORF6487–495/Db (AGPHNDMEI) epitopes conjugated to al-
lophycocyanin were obtained from the NIH Tetramer Core Facility (Emory
University, Atlanta, GA). Cells were stained for 1 h at room temperature in the
dark as previously described (32). Cells were further stained with PerCP-conju-
gated anti-CD8 (clone 53-6.7) and antibodies against the following surface
markers: fluorescein isothiocyanate (FITC)-conjugated anti-CD44 (IM7), FITC-
conjugated anti-CD62L (MEL-14), FITC-conjugated anti-CD27 (LG.7F9),
FITC-conjugated anti-CD69 (H1.2F3), phycoerythrin (PE)-conjugated anti-
CD127 (A7R34), PE-conjugated anti-CD122 (SH4), and PE-conjugated anti-
CD25 (PC61). Staining and analysis were done as previously described (32).
Intracellular cytokine staining. B cells were removed from splenocytes by
panning for 1 h on plates coated overnight with 100 g/ml goat anti-mouse
IgG/IgM (Jackson ImmunoResearch Laboratories, West Grove, PA). The B-
cell-depleted splenocytes were incubated with 1 g/ml of the appropriate peptide
plus 10 U/ml IL-2 and 10 g/ml brefeldin A in complete medium at 37°C for 5 h.
Cells were stained with anti-CD8 antibody and anti-CD44 antibody and then
fixed and rendered permeable before staining with allophycocyanin-conjugated
anti-IFN- (XMG1.2) and PE-conjugated anti-tumor necrosis factor alpha
(TNF-; MP6-XT22), anti-IL-2 (JES6-5H4), or anti-granzyme B (clone 100) as
described previously (46). Analysis was performed on a FACSCalibur flow
cytometer using CellQuest software (BD Immunocytometry Systems, Mountain
View, CA).
BrdU staining. Proliferation of virus-specific CD8 T cells in vivo was mea-
sured by bromodeoxyuridine (BrdU) staining. Latently infected mice with
MHV-68 were given water containing 0.8 mg/ml BrdU (Fisher Scientific, Hamp-
ton, NH) for 5 days. Splenocytes and lung lymphocytes were stained with both
the ORF61524–531/Kb or ORF6487–495/Db tetramer and anti-CD8 then stained
with anti-BrdU Ab according to the BrdU flow kit protocol (BD Pharmingen).
In vivo cytotoxicity assay. The in vivo cytotoxicity assay was performed as
previously described (31). Briefly, naı̈ve C57BL/6 splenocytes were pulsed with
the ORF61524–531 peptide or no peptide and were labeled with 0.5 M CFSE
(Molecular Probes, Eugene, OR) or 10 M CellTracker orange (Molecular
Probes), respectively. Cells were mixed at a 1:1 ratio, and 2  107 cells were
injected intravenously. One day later, mice were sacrificed and collected
spleen cell suspensions were incubated with 20 g/ml 7-amino actinomycin D
(Sigma-Aldrich) for 15 min at room temperature in the dark to label dead
cells. Cells were analyzed by flow cytometry, and specific lysis was calculated
using the following formulas: ratio  (no. CFSE-labeled cells/no. CellTracker
orange-labeled cells) and % of specific lysis  [1  (ratio of naive/ratio of
infected)  100].
Virus neutralization assay. Serum was collected from mice latently infected
with MHV-68. Six threefold dilutions of serum were made in duplicate, starting
at a 1/50 dilution. The diluted serum samples were mixed with 40 to 50 PFU of
MHV-68 and incubated on ice for 1 h. Four hundred microliters of the mixture
was then added to NIH 3T3 monolayers, which were then incubated at 37°C for
1 h. Two milliliters of medium containing carboxymethyl cellulose was added,
and the plates were cultured for 6 days at 37°C. Then monolayers were fixed with
methanol for 15 min and stained with Giemsa stain for at least 4 h, and plaques
were counted microscopically. The dilution (fold) of serum which resulted in a
50% reduction in the number of plaques compared to the no-serum control was
calculated.
CD4 IFN- ELISPOT assay. The IFN- enzyme-linked immunospot (ELISPOT)
assays to quantify CD4 T-cell responses were done as previously described (10).
Briefly, CD4 cells were purified from MHV-68-infected spleens using a CD4
enrichment kit (Stemcell Technologies). Purity was approximately 80 to 90%. A
total of 105 purified cells were added to the first well in triplicate and were
diluted at threefold dilutions for four wells. APCs were prepared by infecting
naı̈ve splenocytes with 1 PFU/cell at 37°C for 1 h and subsequently irradiating the
cells. A total of 5  105 APCs were added in each well. Cells were incubated at
37°C for 36 to 48 h and were developed and analyzed as previously described
(46). Data were expressed as the number of IFN--producing CD4 T cells,
correcting for the exact purity of the sample.
Standard plaque assay and in vitro amplification. Infectious virus titers in the
lungs were determined by standard plaque assays as previously described (40).
To allow amplification of viral titers, a 1/10 dilution of lung homogenates was
added to NIH 3T3 cell monolayers in duplicate and the cells were cultured for 6
days without the addition of carboxymethyl cellulose. An additional 1 ml of
medium was added at day 2. At day 6, cells and supernatants were collected,
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freeze-thawed to release the virus replicating inside the cells, and spun down, and
virus titers in the supernatants were measured using a standard plaque assay.
Quantitative PCR for viral transcripts. Latent viral DNA was quantified by
quantitative fluorescent (QF)-PCR for the ORF50 gene as previously de-
scribed (47).
Statistical analysis. P values were calculated using Student’s t test unless
stated otherwise. P  0.05 was considered significant.
RESULTS
Impaired primary expansion of antiviral CD8 T-cell re-
sponse in the absence of CD80/CD86. It has been reported in
several viral infection models, such as LCMV, influenza virus,
or VSV, that CD80/CD86-CD28 costimulation significantly
impacts the magnitude and function of the antiviral CD8
T-cell response (4, 8, 12, 29, 42, 44, 59). CD8 T cells play a
crucial role in the control of initial replication of MHV-68 and
contribute to long-term immune surveillance (14, 24). There-
fore, we performed detailed analysis of the anti-MHV-68
CD8 T-cell response in CD80/CD86/ mice.
First, to characterize the total cellular response, the numbers
of total lymphocytes in the spleens, MLNs, and lungs were
enumerated at different time points after infection with MHV-
68. One of the hallmarks of MHV-68 infection is the induction
of splenomegaly around 2 to 3 weeks postinfection. As shown
in Fig. 1A, normal splenomegaly was observed in CD80/
CD86/ mice, and the total number of splenocytes was not
affected at any time point. Total lymphocyte numbers in the
MLNs were comparable to those in B6 mice at day 10 but were
decreased by 	2-fold at day 14 (Fig. 1B). The absence of
CD80/CD86 did not affect the number of lymphocytes re-
cruited to the lungs at days 10 and 14 (Fig. 1C). However, the
number of lung-infiltrating lymphocytes was increased during
long-term infection in CD80/CD86/ mice (Fig. 1D).
In order to assess the effect of CD80/CD86 deficiency on the
magnitude of the antiviral CD8 T-cell response, the kinetics
of CD8 T-cell responses specific for the two major epitopes in
C57BL/6 mice, ORF61524–531 and ORF6487–495, were quanti-
fied using MHC/peptide tetramers (Fig. 2). At the peak of the
CD8 T-cell response, the numbers of virus-specific CD8 T
cells in the lung were significantly reduced compared to those
in B6 controls (Fig. 2A and B). The ORF61524–531-specific
response was significantly reduced at day 10 postinfection (Fig.
2A). At day 14, the responses against both epitopes were sig-
nificantly lower: an 	2-fold reduction (Fig. 2A and B). In the
spleen, a more severe reduction was observed (Fig. 2C and D).
The numbers of ORF6487–495-specific CD8
 T cells were re-
duced 	3-fold at day 10 postinfection, although this reduction
was not statistically significant. At day 14, the numbers of
virus-specific CD8 T cells were significantly reduced for both
epitopes: 	4-fold for ORF61524–531 and 	3-fold for ORF6487–495
(Fig. 2C and D). The significant decrease in the number of
virus-specific cells in both organs was due to lower frequencies,
not fewer numbers of cells per organ (Fig. 1A and C) (data not
shown). In the MLNs, the CD8 T-cell response to both
epitopes was reduced at day 14 (Fig. 2E), and this was due to
a decrease in the total number of lymphocytes (Fig. 1B). Data
from Fig. 1 and 2 reveal that CD80/CD86 costimulation sig-
FIG. 1. Normal splenomegaly but enhanced recruitment of mononuclear cells in the lung during persistent MHV-68 infection. Number of total
lymphocytes in the spleen (A), MLN (B), and lung (C and D) were counted at indicated time points. Each point represents data from an individual
animal (A, C, and D). LNs were pooled from three to four mice, and the average cell number was calculated (B). Representative data from two
to four experiments are shown. *, P  0.05; NS, not significant.
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nificantly influences the magnitude of the primary CD8 T-cell
response against MHV-68 infection.
In the spleens, virus-specific CD8 T cells during long-term
infection, days 42 and 97 postinfection, were comparable to
those of B6 controls (Fig. 2C and D). However, there was a
significantly increased number of ORF61524-531-specific CD8

T cells in the lungs of CD80/CD86/ mice at day 68 postin-
fection (Fig. 2A). This was due to an increased number of
lung-infiltrating lymphocytes present in CD80/CD86/ mice
(Fig. 1D).
Altered phenotype and function of MHV-68-specific CD8 T
cells in CD80/CD86/ mice. The numbers of virus-specific
CD8 T cells were maintained during persistent infection de-
spite the reduced numbers at the peak of the response (Fig. 2A
to E). We speculated that the absence of CD80/CD86 costimu-
lation during priming would result in a functionally defective
memory CD8 T-cell population, despite the similarities in
frequencies and numbers. Because CD8 T-cell function fre-
quently correlates with its phenotype (25, 54), we first analyzed
tetramer-positive CD8 T cells for the activation/memory
markers CD44, CD62L, CD127 (IL-7R), CD122 (IL-15R
),
CD27, CD25, and CD69. CD27 expression by ORF61524–531-
specific CD8 T cells in the spleen, measured by cells positive
as well as the mean fluorescent intensity (MFI), was signifi-
cantly reduced in CD28/ and CD80/CD86/ mice (see Fig.
3A). This was not observed in the lungs because the majority of
virus-specific memory CD8 T cells in the lungs were low for
CD27 expression (data not shown), which is in agreement with
the phenotype of memory CD8 T cells in peripheral organs
(54). The absence of CD28 or CD80/CD86 also resulted in
lower expression of CD122 on virus-specific CD8 T cells in
both the spleen and the lungs (Fig. 3B). Expression of CD44,
CD62L, and CD127 was unaffected in both the spleen and the
lungs (data not shown). Interestingly, expression of CD69 was
significantly increased in the lungs (Fig. 3C) but not in the
spleen (data not shown), indicating the virus-specific CD8 T
cells in the lungs have an activated phenotype. A similar pat-
tern was observed with CD25 expression, although the increase
of its expression in the lungs was not significant (data not
shown). The activated phenotype of virus-specific CD8 T
cells in the lungs of CD28/ and CD80/CD86/ mice was
consistent with the increased ability of virus-specific CD8 T
cells to upregulate the effector molecule granzyme B upon
restimulation with peptide in vitro (Fig. 3D); however, this
FIG. 2. Impaired primary CD8 T-cell responses against MHV-68 in the absence of CD80/CD86. The number of CD8 T cells specific for the
ORF61524–531/K
b (A and C) and ORF6487–495/D
b (B and D) epitopes in the lung (A and B) or the spleen (C and D) were measured at indicated
time points by staining with the corresponding MHC/peptide tetramer, anti-CD8, and anti-CD44. Each point represents data from an individual
mouse: open circles, B6 controls; filled circles, CD80/CD86/ mice. Horizontal bars indicate mean values. Representative data from three
independent experiments are shown. *, P  0.05. (E) ORF61524–531- and ORF6487–495-specific CD8
 T-cell responses in the MLN at days 10 and
14 postinfection. LNs were pooled from three to four mice, and the average numbers of cells per LN were calculated. Representative data from
three experiments are shown.
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effect was also observed in the spleen (data not shown). Be-
cause the virus-specific CD8 T cells had an activated pheno-
type and expressed higher levels of effector molecules, we
suspected that they were undergoing proliferation in response
to antigen. To assess their proliferation in vivo, ORF61- and
ORF6-specific CD8 T cells in the lungs and spleens of per-
sistently infected mice were analyzed for BrdU incorporation
over a 5-day period. Despite its activated phenotype, the per-
centages of virus-specific CD8 T cells undergoing prolifera-
tion during the short pulse were not significantly different
between B6, CD28/, and CD80/CD86/ mice in both or-
gans (data not shown).
Altered phenotype of virus-specific memory CD8 T cells in
the absence of CD80/CD86-CD28 costimulation implied that
the function of these cells might also be affected. Therefore,
next we examined the ability of MHV-68-specific CD8 T cells
to produce cytokines by intracellular cytokine staining. Al-
though the frequencies of CD8 T cells producing IFN- in
response to ORF61524–531 and ORF6487–495 peptides were not
significantly lower than those of B6 controls, the mean MFI of
IFN- during long-term infection (but not early time points)
was significantly lower in CD28/ and CD80/CD86/ mice
(Fig. 4A), indicating lower production of this cytokine on a per
cell basis. The impairment was also observed in the virus-
specific CD8 T cells in the lung (Fig. 4B). TNF- production
was not significantly different in both B6 and CD80/CD86/
FIG. 3. Altered phenotype of virus-specific CD8 T cells in CD80/CD86/ mice. Expression of activation/differentiation markers and effector
molecules (panel A, CD27; panel B, IL-15R
 [CD122]; panel C, CD69; panel D, granzyme B) on ORF61524–531/K
b-specific CD8 T cells from
indicated organs were analyzed. All plots are gated on ORF61524–531/K
b-specific CD8 T cells. (A) CD27 expression on ORF61-specific CD8 T
cells in the spleen at day 98 postinfection. Representative plots are shown on the left. The numbers above indicate the average percent CD27
cells of ORF61524–531/K
b-specific CD8 T cells. The numbers below indicate the average MFI for CD27 expression of ORF61524–531/K
b-specific
CD8 T cells. (B) IL-15R
 (CD122) expression at day 110 postinfection. Representative plots are shown on the left, and the average MFI from
the spleen and lungs are shown on the right. (C) CD69 expression in the lungs at day 270 postinfection. Numbers indicate the average percentage
of cells positive for CD69. (D) Intracellular expression of granzyme B at day 205 postinfection. Lung lymphocytes were restimulated with
ORF61524–531 peptide for 5 h and were stained for intracellular IFN- and granzyme B expression. Plots are gated on CD8
 IFN- cells, and the
average MFI is shown. Each figure contains representative data from two to three independent experiments consisting of three to four mice per
group. Error bars and numbers in parentheses indicate standard deviation. *, P  0.05; **, P  0.01.
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mice, as measured by MFI and the percentage of virus-specific
cells producing TNF- (data not shown). There was minimal
IL-2 production in all groups, including B6 controls, consistent
with our previous findings (data not shown) (32a). These re-
sults indicate the specific requirement of CD80/CD86-CD28
costimulation for MHV-68-specific CD8 T cells to maintain
their ability to produce high levels of IFN-. In addition to
cytokine production, an important feature of CD8 T cells is
their ability to recognize and kill virus-infected cells. There-
fore, we analyzed the cytotoxicity of MHV-specific CD8 T
cells with an in vivo cytotoxicity assay. The cytotoxicity against
ORF61524–531-pulsed targets in CD28
/ and CD80/CD86/
mice was comparable to that in B6 controls (Fig. 5).
A hallmark of memory CD8 T cells is their ability to pro-
liferate rapidly upon secondary antigen challenge. Because the
FIG. 4. Gradual loss of IFN- production by virus-specific CD8 T cells generated in the absence of CD80/CD86. Splenocytes from days 10,
14, and 110 postinfection (A) and lung lymphocytes from day 187 postinfection (B) were stimulated with the ORF61524–531 peptide and were
stained for intracellular IFN- expression. A representative plot for gating (gated on CD8 cells) is shown in the top panel in panel A, and the
average MFI for IFN- staining is graphed (A, bottom panels, and B). Each panel contains representative data from two to three independent
experiments consisting of three to four mice per group. Error bars represent 1 standard deviation. *, P  0.05; **, P  0.01; NS, not significant.
FIG. 5. The absence of CD80/CD86 does not alter cytotoxicity. In
vivo cytotoxicity at day 113 postinfection was measured as indicated in
Materials and Methods. Error bars represent 1 standard deviation.
Representative data from two independent experiments consisting of
three to four mice per group are shown.
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phenotype was altered and IFN- production was impaired in
the MHV-68-specific memory CD8 T cells in the absence of
CD80/CD86, we predicted that their ability to mount a sec-
ondary response would also be defective. Indeed, the expan-
sion of ORF61524–531-specific memory CD8
 T cells upon sec-
ondary challenge with a recombinant vaccinia virus expressing
the ORF61524–531 epitope (rVV-ORF61) was severely im-
paired (Fig. 6). The impairment was observed by both the
frequency of ORF61-specific CD8 T cells (Fig. 6A) and the
total number of ORF61-specific CD8 T cells in the spleen
(Fig. 6B). Thus, the results demonstrate that the CD80/CD86-
CD28 costimulatory signal specifically affected the initial ex-
pansion, phenotype, IFN- production, and secondary re-
sponse of MHV-68-specific CD8 T cells, but not TNF-
production or its cytotoxicity.
Humoral responses and CD4 T-cell responses in CD80/
CD86/ mice. Next we tested whether the antiviral antibody
or CD4 T-cell response was affected by CD80/CD86 deficiency.
First, the humoral response was measured using a virus neu-
tralization assay. Serum from either CD28/ or CD80/
CD86/ mice elicited low virus neutralizing activity, confirm-
ing the essential role of the CD80/CD86-CD28 axis in the
germinal center reaction and the induction of high-affinity an-
tiviral antibodies (Fig. 7A) (24). The magnitude of the CD4
T-cell response was measured by an IFN- ELISPOT assay
using purified CD4 splenocytes at day 24 postinfection (Fig.
7B), a time point close to the peak of the response (16), and
day 68 (Fig. 7C), a time point during latent infection. CD4
T-cell responses were not affected at either time point, indi-
cating that CD80 and CD86 are dispensable for the CD4
T-cell response against MHV-68.
Viral reactivation in the absence of CD80 and CD86. As we
observed functional impairments in T-cell responses during
persistent MHV-68 infection, we wished to test whether this
had an impact upon control of the infection. Therefore, we
examined the kinetics of viral replication in the lungs of CD80/
CD86/ mice. The viral titers in the lungs of CD80/CD86/
mice were comparable to those in wild-type B6 controls during
the early phase of the infection; however, low levels of viral
FIG. 6. Defective secondary responses in the absence of CD80/CD86.
(A) Naı̈ve or infected B6, CD28/, or CD80/CD86/ mice were chal-
lenged with 106 PFU of rVV-ORF61 intraperitoneally at day 43 postin-
fection. Frequencies of ORF61524–531/K
b-specific CD8 T cells in the
spleen were measured by tetramer staining 5 days after vaccinia virus
challenge. Representative plots of CD8 gated splenocytes are shown.
The average percentage of tetramer-positive CD8 cells ( standard
deviation) is indicated. Data were analyzed using the Mann-Whitney U
test. *, P  0.05; **, P  0.01. (B) Total numbers of ORF61524–531/K
b-
specific CD8 T cells in the spleen 5 days postchallenge. *, P  0.05;
**, P  0.01 (analyzed by Student’s t test). Representative data from two
independent experiments consisting of three to four mice per group are
shown.
FIG. 7. Ab and CD4 T-cell responses in CD80/CD86/ mice.
(A) Virus neutralizing Ab activity in the serum of infected mice at day
110 postinfection was assayed on NIH 3T3 cells as indicated in Mate-
rials and Methods. (B and C) The virus-specific CD4 T-cell response
was measured at days 24 (B) and 68 (C) postinfection by an IFN-
ELISPOT assay on purified CD4 cells. Representative data from two
independent experiments consisting of three to four mice per group
are shown. Error bars represent 1 standard deviation. *, P  0.05;
**, P  0.01; NS, not significant.
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replication were observed in CD80/CD86/ mice at day 42
postinfection (Fig. 8A). Viral replication was consistently ob-
served at later time points during latency in the lungs of CD80/
CD86/ mice, while no virus replication was detectable in B6
mice (Fig. 8B). This was very surprising, as no virus reactiva-
tion was detected in either the two reports of MHV-68 infec-
tion in CD28/ mice (24, 26) or in our experiments (Fig. 8B),
and these mice would be expected to have a very similar phe-
notype to CD80/CD86/ mice. This result was confirmed by
QF-PCR for the ORF50 gene performed on DNA extracted
from the lungs of persistently infected mice, which showed
significantly higher levels of viral genomes in CD80/CD86/
mice (Fig. 8C). An ex vivo viral reactivation assay using mouse
embryonic fibroblasts (48) also showed a higher frequency of
reactivation (data not shown).
Although three different assays demonstrated viral reactiva-
tion in the lungs of latently infected CD80/CD86/ mice, the
level of virus detected was close to the limit of detection in
each assay. Therefore, we cultured lung homogenates from
infected mice on NIH 3T3 monolayers to provide an in vitro
amplification step and then subsequently determined the titer
of the supernatants by a standard plaque assay (see Materials
and Methods). The results of a representative experiment of
the in vitro-amplified plaque assay on lung samples from day
182 postinfection lung samples are shown in Table 1. While no
viral replication was observed in the B6 lungs even after the
amplification step, viral titers of the CD80/CD86/ lungs
were amplified to over 100,000-fold, confirming the existence
of replicating virus during persistence.
To determine whether the higher viral burden observed in
the CD80/CD86/ mice was restricted to the lungs, we ana-
lyzed the latent viral load in the spleen by QF-PCR. Viral
genome copies were lower in CD80/CD86/ mice compared
to B6 controls at days 14, 21, and 28 postinfection, as is also
seen in other strains that fail to make a germinal center re-
sponse and expand the number of latently infected B cells (Fig.
9) (26). The number of latent viral genomes in the spleen at
day 42 was the same as in B6 mice, and no viral replication was
detected by a plaque assay, indicating that immune surveil-
lance is maintained in the spleen (Fig. 9) (data not shown).
Similar data were obtained at later time points during persis-
tent infection (day 110 postinfection) (data not shown).
Surveillance of MHV-68 by CD80/CD86 is independent of
CD28 and CTLA-4. Two previous studies reported that
CD28/ mice control MHV-68 latency normally, and no re-
activation was observed (24, 26). To confirm these results, we
performed the in vitro-amplified plaque assay on CD28/
mice. Viral reactivation was consistently observed in CD80/
CD86/, but not CD28/, mice, indicating that surveillance
of MHV-68 by T cells through CD80/CD86 is mediated
through a CD28-independent signal (Table 2). CD80/ and
CD86/ single-knockout mice controlled viral replication,
showing that the two receptors play redundant roles in viral
control. As previously reported (6, 26), high levels of viral
replication were detected from lungs of CD40/ mice, which
FIG. 8. Viral reactivation in the lungs of CD80/CD86/ mice. (A
and B) C57BL/6 and CD80/CD86/ mice were infected intranasally
with 400 PFU of MHV-68, and lungs were harvested at the indicated
time points and assayed for viral titers by a standard plaque assay using
NIH 3T3 cells. (A) Representative data of viral kinetics in the lungs
from two independent experiments are shown. (B) Each time point
represents an independent experiment. (C) The number of viral ge-
nome copies in the lungs was measured by QF-PCR for the ORF50
gene. Each point represents data from an individual mouse. *, P 
0.05; *, P  0.01.
TABLE 1. Viral reactivation at day 182 postinfection detected
by an in vitro-amplified plaque assay
Mouse strain






CD80/CD86/ 150 9.4  107
40 3.2  107
150 3.1  107
95 8.9  107
a Shown are lung viral titers measured by a standard plaque assay (P  0.01)
and viral reactivation measured by an in vitro-amplified plaque assay as de-
scribed in Materials and Methods (P  0.05). Each number represents the lung
viral titer of an individual mouse. Representative data from six independent
experiments are shown.
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was confirmed by in vitro amplification and subsequent plaque
assay (Table 2).
A key difference between CD28/ and CD80/CD86/
mice is that CTLA-4 signaling is present in CD28/ mice but
not CD80/CD86/ mice. Some earlier studies have indicated
a positive costimulatory role for CTLA-4 (56, 58); therefore,
we sought to investigate whether the CD28-independent con-
trol of MHV-68 by CD80/CD86 is mediated by CTLA-4. Be-
cause CTLA-4/ mice develop a severe lymphoproliferative
disease (50), we designed experiments in which CTLA-4 was
blocked in vivo using a monoclonal antibody. CD28/ mice
were infected with MHV-68 and were treated with a blocking
anti-CTLA-4 MAb or a control Ab for 2 weeks. Whether the
CTLA-4 blockade occurred in weeks 1 and 2 postinfection or
when blockade was initiated 40 days postinfection, no viral
reactivation was detected by in vitro-amplified plaque assay
(11/11 mice treated with anti-CTLA-4, pooled from three in-
dependent experiments, had 0 PFU/lung). Anti-CTLA-4 treat-
ment also did not alter the latent viral load in the spleens of
CD28/ mice, as assessed by quantitative PCR: anti-CTLA-4
treated, (4.1  2.6)  103 viral genomes/300 ng spleen; ham-
ster IgG treated, (4.4  1.5)  103 viral genomes/300 ng spleen
(P  0.86).
The efficacy of the anti-CTLA-4 MAb was confirmed by its
ability to enhance an in vitro mixed lymphocyte reaction (data
not shown). When infected wild-type C57BL/6 mice were
treated with an anti-CTLA-4 MAb from days 25 to 39 postin-
fection, there were significant increases in the numbers of
splenocytes [anti-CTLA-4 treated, (3.08  0.50)  108 cells/
spleen; hamster IgG treated, (1.31  0.42)  108 cells/spleen;
P  0.004] and CD4 T cells with an activated (CD44
CD62Llo) phenotype (anti-CTLA-4 treated,: 48.9%  6.2% of
CD4 T cells; hamster IgG treated, 35.1%  4.9%; P  0.02).
These results concur with the current notion that CTLA-4 is a
negative regulator of T-cell responses and functions in a sim-
ilar fashion in the MHV-68 model. Therefore, we conclude
that the CD28-independent surveillance of MHV-68 mediated
by CD80 and CD86 was also independent of CTLA-4.
DISCUSSION
Both cellular and humoral arms of the immune system play
important roles in the control of MHV-68. CD4 and CD8 T
cells, but not Abs, mediate the control of acute viral replication
in the lungs (14, 37). During latency, CD4 and CD8 T cells
and neutralizing Abs all significantly contribute to the surveil-
lance of viral reactivation (24, 37, 39, 45). The generation of
CD4 and CD8 T-cell and Ab responses is greatly influenced
by the “classical” costimulatory molecules, CD80 and CD86.
Animals lacking either CD28 or CD80/CD86 have impaired
humoral and cellular responses to viral infections, although
their impact on viral control differs between different models
(3). The CD80/CD86-CD28 costimulatory pathway is critical
for germinal center formation in all models, leading to defec-
tive class switching and impaired neutralizing Ab production
(5, 29, 44, 59). In LCMV, VSV, and influenza virus infections,
the absence of this costimulatory pathway results in the reduc-
tion of the antiviral CD8 T-cell response, as measured by
either cytotoxicity or the number of virus-specific CD8 T cells
(4, 27, 29, 42). The effects of CD28 deficiency in MHV-68
infection have been studied previously by two groups (24, 26).
Similar to other viral models, the antiviral humoral response
was severely impaired (24, 26). However, minimal impairments
were detected in the anti-MHV-68 cellular response. The only
defects reported by these two reports were impaired IFN-
production by splenocytes upon recall in vitro at day 7 postin-
fection but not at later time points (26) and slightly (though
not significantly) reduced IFN- production by antiviral CD4 T
cells (24), but no impairments were observed in the antiviral
CD8 T-cell response.
Due to the ample evidence of this costimulatory pathway
having a significant effect in amplifying the antiviral CD8
T-cell response (4, 8, 42), we utilized CD80/CD86/ mice to
characterize the antiviral immune response, mainly focusing on
the CD8 T-cell response. The primary virus-specific CD8
T-cell responses in the spleen, lung, and the MLNs, as mea-
sured by MHC/peptide tetramers, were significantly reduced in
FIG. 9. Establishment of latency in the spleens of CD80/CD86/
mice. The latent viral loads in the spleens were measured by QF-
PCR for the ORF50 gene at the indicated time points postinfection.
Representative data from two independent experiments are shown.
*, P  0.05.
TABLE 2. Surveillance of latency requires either CD80
or CD86 and is independent of CD28
Mouse strain Daypostinfection
Viral titer by plaque assaya:
Standard Amplified
Expt 1
C57BL/6 41 0, 10, 0, 10 0, 0, 0, 0
CD80/ 41 0, 0, 0 0, 0, 0
CD86/ 42 0, 0, 40 0, 0, 0
CD28/ 41 0, 10, 0 0, 0, 0
CD80/CD86/ 41 0, 30, 40 0, 6.3  105, 1.0  105
CD40/ 41 930, 950, 870 8.1  107, 7.7  107,
7.9  107
Expt 2
C57BL/6 110 0, 0, 0, 0 0, 0, 0, 0
CD80/ 97 0, 0,150 0, 0, 0
CD86/ 97 0, 0, 0 0, 0, 0
CD28/ 110 0, 0, 0, 0 0, 0, 0, 0
CD80/CD86/ 100 1,250, 510,
440
1.8  105, 110, 0
a Lungs were harvested at day 40 or 41, and viral titers were measured by
either a standard or an in vitro-amplified plaque assay. Each number represents
the lung viral titer of an individual mouse. Data from two independent experi-
ments are shown.
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CD80/CD86/ mice (Fig. 2A to E). The defect was most
significant at day 14 postinfection, resulting in a 2- to 	4-fold
reduction of virus-specific CD8 T cells in the lungs, draining
lymph nodes, or spleen. Despite the defective initial expansion,
the number of virus-specific CD8 T cells was not affected by
the absence of CD80/CD86 at later time points (Fig. 2A to D).
In acute infections such as with LCMV and influenza virus, the
defective initial expansion in CD28/ mice led directly to
decreased numbers of memory CD8 T cells, which indicates
that the effector CD8 T cells at the peak of the response
underwent programmed contraction (4, 42). In contrast, in the
MHV-68 model, the numbers of virus-specific memory CD8
T cells were normal despite the impaired initial expansion (Fig.
2A to D), suggesting that the programmed contraction may be
affected by persisting virus. The number of ORF61524–531/K
b-
specific CD8 T cells was increased in the lungs of CD80/
CD86/ mice but not B6 or CD28/ mice during latency,
and this is likely due to the low level of viral reactivation
occurring in the lungs of these mice.
The phenotype of virus-specific CD8 T cells often offers in-
sights into their functional status (25, 54). Despite the similarity in
the number of virus-specific CD8 T cells, their phenotypes dif-
fered significantly in CD28/ and CD80/CD86/ mice (Fig. 3).
CD27 and IL-15R
 were significantly downregulated on MHV-
68-specific memory CD8 T cells (Fig. 3A and B). CD27 is a
costimulatory molecule that belongs to the tumor necrosis factor
receptor family and is known to be expressed on a subset of
memory CD8 T cells, mainly in lymphoid organs such as the
spleen and lymph node (25, 51, 54, 55). Lower CD27 expression
also indicates that the memory CD8 T cells are less sensitive to
CD70-CD27 costimulatory signals and may be one reason why
the function of these cells are impaired. The role of the CD70-
CD27 interaction in controlling MHV-68 infection and MHV-68-
specific immune responses has not yet been addressed and will be
an area of interest due to the prominent role of CD27 in antiviral
T-cell responses (20–22). IL-15R
 is also known to be upregu-
lated upon differentiation of effector T cells into memory T cells,
which are maintained in an IL-15-dependent manner (33). How-
ever, in chronic viral infections such as MHV-68, the survival of
virus-specific memory CD8 T cells is IL-15 independent (32, 55),
complicating the role of IL-15R
 in this model. We suggest that
downregulation of CD27 and IL-15R
 reflects defective differ-
entiation of virus-specific CD8 T cells due to suboptimal prim-
ing in the absence of CD80/CD86.
The defective differentiation of virus-specific CD8 T cells
in the absence of CD80/CD86 costimulation is supported by its
functional defects. Impaired production of IFN-, but not
TNF-, by virus-specific CD8 T cells was observed during
long-term surveillance (Fig. 4A and B). Lower IFN- produc-
tion on a per cell basis by virus-specific CD8 T cells, as
measured by the MFI of IFN- by intracellular staining, has
been observed during persistent LCMV-T1b infection (43).
Compared to chronic LCMV infection, the amounts of chronic
antigen and replication, and thus the frequency of virus-spe-
cific CD8 T cells encountering antigen, are significantly lower
in MHV-68 infection. This may be the reason why the defect in
IFN- production is not observed in wild-type C57BL/6 mice.
It is tempting to hypothesize that CD80/CD86 signals prevent
the loss of IFN- production by the virus-specific CD8 T
cells; and in the absence of this costimulatory signal, even a low
level of antigen causes the defect in IFN- production. This is
supported by our findings that the decrease in IFN- produc-
tion in CD8 T cells from CD80/CD86/ mice is not ob-
served during the acute response at 10 and 14 days postinfec-
tion (Fig. 3A). Moreover, this deficiency was not seen when
CD28/ or CD80/CD86/ mice were infected with an
ORF73-deficient virus, a mutant virus which is unable to es-
tablish latency (17, 30), further supporting the role of chronic
antigen in impairing IFN- production (S.F. and E.J.U., un-
published observation).
The defective secondary response of MHV-specific-CD8
memory T cells upon challenge by rVV-ORF61 further sup-
ports this idea that differentiation of fully competent memory
CD8 T cells are hindered in the absence of CD80/CD86
costimulation (Fig. 6A and B). However, despite the defects
described above, cytotoxicity was unaffected, as measured by
an in vivo cytotoxicity assay (Fig. 5). This result is consistent
with the previous report that cytotoxicity is not affected in the
absence of CD28 (26) and reveals a selective effect of CD80/
CD86-CD28 costimulation on different functions of MHV-68-
specific CD8 T cells.
CD28/ mice were reported to control MHV-68 latency
without any signs of virus reactivation (24, 26). Therefore, the
detection of viral replication in the lungs of latently infected
CD80/CD86/ mice came as a surprise (Fig. 8A to C). Viral
kinetic studies revealed that the initial viral replication in the
lungs is controlled normally, and viral reactivation occurs
during latency (40 days postinfection) (Fig. 8A). Viral reac-
tivation was not observed when CD80/CD86/ mice were
infected with an ORF73-deficient virus (S.F. and E.J.U., unpub-
lished observation). Therefore, the most likely explanation is that
the initial replication in the lungs is controlled normally, and viral
reactivation occurs only after latency is established.
During MHV-68 latent infection, defects in any one com-
partment (CD4, CD8, or humoral) does not result in viral
recrudescence. However, depletion of either T-cell subset in
the absence of neutralizing Abs results in low levels of viral
replication in the lungs (24). Both CD28/ and CD80/
CD86/ mice are unable to produce neutralizing Abs (Fig.
7A). Previous studies have suggested that the main effector
mechanism of antiviral CD4 T cells during latency is the
production of IFN- (9, 34, 38), and this function seems to be
maintained in the absence of CD80/CD86-CD28 costimulation
(Fig. 7B and C). Although antiviral CD4 T-cell responses to
LCMV, HSV-1, and influenza virus are significantly affected by
CD80/CD86-CD28 costimulation (5, 8, 12), our results and
previous reports show that CD4 T-cell responses to MHV-68
are normal in CD28/ mice (24, 26), indicating that the de-
pendence of antiviral CD4 T-cell responses on this pathway
differs among different viruses. Normal antiviral CD4 T-cell
responses imply that impaired antiviral CD8 T-cell functions
in addition to the impaired humoral response are the cause of
the low level of viral reactivation observed. Virus-specific
CD8 T cells are impaired in the production of IFN- (Fig. 4),
which is a key mediator of viral control during latency (11, 35,
52). The virus-specific CD8 T cells are severely defective in
expansion upon secondary antigen encounter (Fig. 6), and
their phenotype implies a defective differentiation state (Fig.
3A and B). Thus, the defects observed in addition to the
impaired humoral immune response likely weaken the immu-
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nological surveillance of MHV-68 in the CD28/ and CD80/
CD86/ mice. Virus-specific CD8 T cells in the lungs of
CD28/ and CD80/86/ mice have an activated phenotype
indicated by significantly higher CD69 expression (Fig. 3C) and
express higher levels of granzyme B upon restimulation (Fig.
3D), suggesting recent encounter with viral antigen. Therefore,
there seems to be a partial loss of viral control in these mice.
However CD28/ mice clearly prevent virus reactivation, but
reactivation does occur in CD80/86/ mice (Fig. 8 and Table
2). Therefore, the main defect of immune surveillance ob-
served in CD80/86/ mice is independent of CD28, and we
also showed it is independent of CTLA-4, the only other
known ligand for CD80/86. Two previous studies have pro-
posed the existence of an additional receptor(s) for CD80/
CD86 (28, 57). Yamada et al. demonstrated that survival of
cardiac allografts in CD28/ mice could be prolonged by
antibody blockade of CD86 and that this CD86-mediated pos-
itive signal is independent of CTLA-4 (57). This result implied
that there is an additional receptor for CD86, although it
differs from the results in our study in which the positive signal
is mediated by either CD80 or CD86 (Table 2). Mandelbrot et
al. provided evidence of CD80- and CD86-dependent prolif-
eration of CD28/ CTLA-4/ CD4 T cells in vivo and in
vitro, implying the existence of a CD28-, CTLA-4-independent
signal mediated by CD80/CD86 (28). Therefore, we hypothe-
size that an as yet unidentified receptor for CD80/CD86 is
necessary, in addition to CD28, to provide an essential signal to
CD8 T cells to facilitate immune surveillance and prevent
MHV-68 reactivation in the lungs.
In summary, our study reveals a key role of CD80/CD86 in
controlling antiviral immunity and the immunological surveil-
lance of MHV-68. The magnitude of the primary virus-specific
CD8 T-cell response and the induction of neutralizing Abs
are significantly affected. Furthermore, the function of the
virus-specific CD8 T cells is severely impaired. Finally, a
CD28, CTLA-4-independent CD80/CD86 signal is required
for control of viral reactivation. These results provide new
insights into the role of costimulatory molecules in chronic
viral infections, an area currently poorly characterized, and will
potentially lead to the rational design of vaccines or therapies
against chronic gammaherpesvirus infections.
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